Peptech reports 'outstanding' results
18 June, 2003 by Jeremy TorrBiotech Peptech announced what it described as "outstanding" results from pre-clinical trials on its anti-Tumour Necrosis Factor (anti-TNF) antibody as a treatment for rheumatoid arthritis (RA).
Imugene completes $2m placement
17 June, 2003 by Melissa TrudingerVeterinary biotechnology company Imugene has completed a $AUD2 million placement to institutional and professional high net worth investors.
Genetic Technologies receives $US150,000 for patent license
16 June, 2003 by Melissa TrudingerTexan company Inguran has paid $US150,000 to Melbourne-based Genetic Technologies to use the company's non-coding patents for genetic testing of livestock in the USA, Colombia and Brazil.
Laser lab to improve artificial heart design
13 June, 2003 by Jeremy TorrA $1.5million laser diagnostic laboratory could help researchers cut down thrombosis risks for artificial heart patients, using the latest Particle Image Velocimetry (PIV).
Tissue Growth and Repair CRC backs a winner
13 June, 2003 by Jeremy TorrShooting the nag for not winning could be a thing of the past thanks to the CRC for Tissue Growth and Repair’s work on IGF-I (insulin-like growth factor-I) to stimulate tissue repair.
Imugene itching to launch product
12 June, 2003 by Jeremy TorrVet biotech Imugene is pinning big hopes on its recombinant gene-based flea control vaccine currently on trial at Murdoch University.
Genetraks invests $1m to fast-track development
11 June, 2003 by Pete YoungCashed-up young biotech Genetraks Pty Ltd is investing more than $1 million to dramatically accelerate the time to market of its gene-based diagnostic and monitoring tools.
MIF blocking drugs being developed by Cortical
11 June, 2003 by Melissa TrudingerOne of Australia's newest start-up companies has spun out of Monash University with a focus on finding therapeutics targeting the macrophage inhibitory factor (MIF).
GM's lambs are inviting slaughter
11 June, 2003 by Graeme O'NeillGraeme O'Neill discovers that the biotech community needs a whole new strategy to win points on GM crops
Africa needs GM crops: scientist
10 June, 2003 by Graeme O'NeillAfrican plant geneticist Dr Florence Wambugu has accused Western activists, seeking to block the introduction of genetically modified (GM) crops in Africa, of having “no understanding” of the needs of African farmers and communities.
GroPep, CSL amend agreement
10 June, 2003 by Melissa TrudingerAdelaide company GroPep and cell culture reagent distribution partner CSL have amended their sales and distribution agreement to reflect expected demand for GroPep's growth factor products by extending the agreed minimum sales targets from the 2005-2006 financial year through to the end of the 2010 financial year, when the agreement ends.
Trial tapeworm vaccine takes the bacon
06 June, 2003 by Jeremy TorrInitial research by a PhD student at the Bioproducts Cooperative Research Centre (CRC) in Melbourne has shown an edible tapeworm vaccine is possible -- for pigs.
Benitec locks in US and UK patents for RNAi tech
05 June, 2003 by Pete YoungGene silencing company Benitec has locked in place US and UK patents for the technology which underpins a recent global licensing pact signed by the Brisbane biotech.
Bionomics scores with new appointment
05 June, 2003 by Melissa TrudingerFormer Merck Research Laboratories director of neuropharmacology Dr Mark Varney has joined Adelaide company Bionomics as VP of drug discovery, where he will lead the company's epilepsy and central nervous system drug discovery program.
Novogen drug results released at ASCO meeting
04 June, 2003 by Melissa TrudingerNovogen subsidiary Marshall Edwards' anti-cancer drug phenoxodiol has featured at the American Society of Clinical Oncology meeting in Chicago this week, with Yale researchers presenting data demonstrating that the compound is added to low levels of standard chemotherapy agent cisplatin, the size of human ovarian cancer tumours in animal models by up to 75 per cent.
